

**AVEXIS - VT New Drug Submission - ZOLGENSMA® June 2019**

<b>NDC</b>	<b>DRUG_PROD_DESC</b>
071894-120-02	ZOLGENSMA® (onasemnogene abeparvovec-xioi) is a landmark one-time, adeno-associated virus (AAV) vector-based gene-therapy treatment for pediatric patients less than 2 years of age with spinal muscular atrophy (SMA) with bi-allelic mutations in the survival motor neuron 1 (SMN1) gene. Zolgensma® is designed to address the genetic root cause of SMA by providing a functional copy of the human SMN gene to halt disease progression through sustained SMN protein expression with a single, one-time intravenous (IV) infusion. (Each NDC correlates to weight; this is a weight-based one-time gene-therapy treatment).
071894-121-03	same as above
071894-122-03	same as above
071894-123-03	same as above
071894-124-04	same as above
071894-125-04	same as above
071894-126-04	same as above
071894-127-05	same as above
071894-128-05	same as above
071894-129-05	same as above
071894-130-06	same as above
071894-131-06	same as above
071894-132-06	same as above
071894-133-07	same as above
071894-134-07	same as above
071894-135-07	same as above
071894-136-08	same as above
071894-137-08	same as above
071894-138-08	same as above
071894-139-09	same as above
071894-140-09	same as above
071894-141-09	same as above

INTRODUCED_TO_MARKET_DATE	WAC_AT_INTRODUCTION
5/24/2019	\$2,125,000.00
5/24/2019	\$2,125,000.00
5/24/2019	\$2,125,000.00
5/24/2019	\$2,125,000.00
5/24/2019	\$2,125,000.00
5/24/2019	\$2,125,000.00
5/24/2019	\$2,125,000.00
5/24/2019	\$2,125,000.00
5/24/2019	\$2,125,000.00
5/24/2019	\$2,125,000.00
5/24/2019	\$2,125,000.00
5/24/2019	\$2,125,000.00
5/24/2019	\$2,125,000.00
5/24/2019	\$2,125,000.00
5/24/2019	\$2,125,000.00
5/24/2019	\$2,125,000.00
5/24/2019	\$2,125,000.00
5/24/2019	\$2,125,000.00
5/24/2019	\$2,125,000.00
5/24/2019	\$2,125,000.00

MARKETING_PRICING_PLAN	ESTIMATED_PATIENTS
<p>The marketing for ZOLGENSMA® includes promotion to physicians, direct to consumer promotion, and other types of marketing (e.g., educational programs)</p>	<p>From June to December of 2019, we estimate that the average number of US patients prescribed ZOLGENSMA® across all NDCs listed will be 150</p>
same as above	same as above
same as above	same as above
same as above	same as above
same as above	same as above
same as above	same as above
same as above	same as above
same as above	same as above
same as above	same as above
same as above	same as above
same as above	same as above
same as above	same as above
same as above	same as above
same as above	same as above
same as above	same as above
same as above	same as above
same as above	same as above
same as above	same as above
same as above	same as above
same as above	same as above

BREAKTHROUGH_THERAPY_INDICATOR	PRIORITY_REVIEW_INDICATOR	ACQUISITION_DATE
Yes	Yes	N/A



**GENERAL\_COMMENTS**

We believe that all information submitted by AveXis to the Department of Vermont Health Access or to the Attorney General under Vt. Stat. tit. 18 §§ 4635 or 4637, including all information contained in this submission, is confidential and proprietary commercial or financial information not subject to disclosure, including under the Vermont Public Records Act (Subchapter 3 of Chapter 5 of the Vermont Statutes) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all AveXis' related information herein be maintained to the maximum extent permitted by law. To the extent that any of this designated information is requested, whether under Vermont Public Records Act (Subchapter 3 of Chapter 5 of the Vermont Statutes) or otherwise, we request that AveXis be notified of the request and afford us the opportunity to submit objections to disclosure.

same as above

same as above